Breakingviews on Twitter
Search League Tables

Sunday, 29 May 2016

Even after the knock, Novo Nordisk's rating is fat

Crash diet

The Danish drugmaker lost about $14 bln in market value after U.S. regulators held off approving a new insulin treatment. As the world grows obese, the diabetes specialist should profit handsomely. But the shares look rich, even after the 13 pct markdown.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.

Sign In

(Launches in a new window)